Page last updated: 2024-09-03

rb 6145 and Breast Cancer

rb 6145 has been researched along with Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chaplin, DJ; Davis, P; Devkota, L; Gerberich, JL; Hamel, E; Kuch, B; MacDonough, MT; Mason, RP; Mondal, D; Pinney, KG; Ramirez, AJ; Shi, Z; Strecker, TE; Trawick, ML; Wang, Y; Winn, BA	1

Other Studies

1 other study(ies) available for rb 6145 and Breast Cancer

Article	Year
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia. Journal of natural products, 2020, 04-24, Volume: 83, Issue:4 Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Hypoxia; Colchicine; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; NADPH-Ferrihemoprotein Reductase; Prodrugs; Stilbenes; Tubulin	2020

Article

Year

Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.

Journal of natural products, 2020, 04-24, Volume: 83, Issue:4

Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Hypoxia; Colchicine; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; NADPH-Ferrihemoprotein Reductase; Prodrugs; Stilbenes; Tubulin

2020